Miguel Forte

Currently an Entrepreneur in Residence (EiR) with AdBio Partners, this biotech executive also consults through mC4Tx to several organizations, including acting as CEO, Professor at Lisbon University and member of the Board of Directors and Executive Committee for Alliance for Regenerative Medicine (ARM).

They were appointed President-Elect and member of the Board of Directors for the International Society of Cell and Gene Therapy (ISCT) from May 2022. Previously, they served as Chief Commercialization Officer and Chair of the ISCT Commercialization Committee (2014-2020), where they expanded the industrial community and strengthened the Committee’s representation of the industrial translational objectives and needs of society membership.

The executive was also CEO of Bone Therapeutics (2019-2022), leading the company through strategic refocus, multiple successful raises, and a successful M&A transaction. Prior to that, they were CEO of Zelluna Immunotherapy (2017-2019), where they established the corporate structure, raised funds, built the team, and launched the strategy for solid tumors allogeneic C&GT. They were CMO/COO of TxCell from 2010-2017, where they established and led the professional C&GT product translation development for autoimmune diseases, participating in the company IPO and several successful raises.

The executive has also held executive positions at UCB and Nabi Pharmaceuticals and has extensive clinical, academic, and regulatory experience in Portugal and at the European Medicines Agency (EMA), including serving as a CHMP member.

They hold an M.D. and a Specialist in Infectious Diseases from the Faculty of Medicine, University of Lisbon, a Ph.D. in Immunology from the University of Birmingham, and a certificate in Health Technologies Economics from the Stockholm School of Economics. The executive is also a Fellow of the Faculty of Pharmaceutical Medicine of the RCP in the UK.